Why Analysts See the ARS Pharmaceuticals Story Shifting Amid Changing Growth and Market Risks [Yahoo! Finance]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Yahoo! Finance
This modest adjustment reflects a balance between optimism regarding strong product growth and caution related to ongoing market challenges. Stay tuned to discover how shifting analyst perspectives could impact your outlook on the ARS Pharmaceuticals story going forward. Stay updated as the Fair Value for ARS Pharmaceuticals shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on ARS Pharmaceuticals. What Wall Street Has Been Saying ?? Bullish Takeaways Analysts across multiple firms highlight Neffy's accelerating adoption and outperformance against competitors as a primary growth engine for ARS Pharmaceuticals. Oppenheimer notes that Q3 financials were strong, with $32.5 million in revenue surpassing both consensus and internal estimates. This supports their continued Outperform rating. The firm sees further upside from upcoming marketing efforts, real-world evidence, and expanded formulary coverage in 2026.
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific MeetingGlobeNewswire
- EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing =15 kg to <30 kgGlobeNewswire
- ARS Pharmaceuticals (NASDAQ:SPRY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- ARS Pharmaceuticals (NASDAQ:SPRY) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use [Yahoo! Finance]Yahoo! Finance
SPRY
Earnings
- 11/10/25 - Miss
SPRY
Sec Filings
- 1/21/26 - Form SCHEDULE
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- SPRY's page on the SEC website